STOCK TITAN

Aclarion Inc - ACON STOCK NEWS

Welcome to our dedicated news page for Aclarion (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aclarion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aclarion's position in the market.

Rhea-AI Summary
Aclarion, a healthcare technology company, has announced that Dr. Roger Hartl, a renowned neurosurgeon, will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain noninvasively. Dr. Hartl will have access to an MRI center authorized to perform Nociscans in New York City, adding to the existing site in Denver. Aclarion plans to report on Nociscan volumes before the end of the year and include this metric in quarterly reporting from 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, announced that its Nociscan platform will be presented at the NIH HEAL Initiative BACPAC Research Program. Nociscan is a decision support tool that helps physicians identify the location of chronic low back pain. It is being utilized in two leading low back pain trials within the HEAL Initiative. The NIH HEAL Initiative aims to address the opioid crisis by funding research on chronic low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
none
-
Rhea-AI Summary
Porter Hospital in Denver has become the first facility to offer Nociscan technology for chronic low back pain patients. The technology measures biomarkers to pinpoint the source of pain and has been shown to improve patient outcomes and reduce costs. Aclarion, the healthcare technology company behind Nociscan, is expanding its footprint in Colorado with AdventHealth Porter. The addition of Nociscan to the hospital's diagnostic evaluation is expected to improve treatment strategies and provide personalized biomarker data to physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
none
Rhea-AI Summary
Aclarion's Nociscan cost-effectiveness study showcased at medical decision making meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
none
-
Rhea-AI Summary
Aclarion and ATEC Spine form strategic partnership to integrate Nociscan surgical decisioning technology with AlphaInformatiX platform for spine surgery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.28%
Tags
partnership
-
Rhea-AI Summary
Aclarion announces engagement of ten KOL surgeons to drive market traction and reimbursement. Company poised to report critical metrics for value creation. Nociscan technology shows durable clinical outcomes and potential to save healthcare system $500M annually. Aclarion selected for NIH-funded BEST Trial. CLARITY Trial to launch in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.77%
Tags
none
Rhea-AI Summary
Aclarion, Inc. was unable to file its Quarterly Report on time but has since filed it on August 25, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, has announced a commercial agreement with The Imaging Center in Grand Rapids, MI. The agreement will provide physicians with access to Nociscan, an AI-enabled decision support tool for identifying the source of chronic low back pain. This partnership presents a marketing opportunity for spine surgeons, pain management physicians, and chiropractors. Aclarion aims to expand patient access through commercial agreements and improve patient care while reducing costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
77.97%
Tags
none
Aclarion Inc

Nasdaq:ACON

ACON Rankings

ACON Stock Data

2.33M
1.93M
2.32%
1.66%
2.22%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States
Broomfield